As β-blocker treatment has emerged as an effective treatment modality for heart failure, there is a general view that PDE4 protects the heart against sustained adrenoreceptor stimulation since βARs activation induces cardiac hypertrophy and apoptosis via the cAMP-PKA signaling activation [13]. Here, PDE4A is linked to heart failure.